Shaun Chilton – CEO, Clinigen Group, UK
A British success story, Clinigen Group provides companies with services in portfolio and product lifecycle management on a global basis. Its CEO, Shaun Chilton, talks to us about the value…
Address: Department for Business, Innovation & Skills, 1 Victoria Street, London SW1H 0ET, United Kingdom
Tel: +44 (0)20 7215 5000
Web: https://www.gov.uk/government/organisations/department-for-business-innovation-skills
The Department for Business, Innovation and Skills (BIS) is building a dynamic and competitive UK economy by: creating the conditions for business success; promoting innovation, enterprise and science; and giving everyone the skills and opportunities to succeed. To achieve this it will foster world-class universities and promote an open global economy. BIS – Investing in our future
The Department for Business, Innovation and Skills (BIS) has an important role at the heart of government as the ‘department for growth’.
That’s why BIS is leading work across government to develop a more balanced and sustainable model for growth. We are building on the Strategy for Sustainable Growth, published in July, with a view to publishing a White Paper in the autumn.
British business can’t prosper while the risk of a debt crisis hangs over the economy. Striking the right balance between making savings and promoting sustainable growth is crucial. This is not just about cuts, but about creating a stable environment that enables businesses to invest and grow with confidence.
We aim to create an enterprise culture where everyone with talent is inspired to turn ideas into successful enterprises and get rid of unnecessary barriers that can stifle growth.
There are three key ways BIS is contributing:
x promoting business and innovation;
x creating a highly-skilled workforce and;
x promoting free and open markets.
The Government, led by BIS, wants to rebalance the economy. This means moving away from an economy reliant on debt to a sustainable one that is greener and more technologically advanced. And it means creating opportunities which are spread more across the regions, and through those sectors where the UK is strong and can add real value.
In a world where there is less money, the role of the state needs to change to get a smarter balance of public and private investment in the economy. We will refocus public spending on those areas where it has the greatest impact on growth and make sure that wider Government policy protects and supports the business environment.
A British success story, Clinigen Group provides companies with services in portfolio and product lifecycle management on a global basis. Its CEO, Shaun Chilton, talks to us about the value…
Having recently joined the UK operations of AstraZeneca after a varied international career, Laurent Abuaf shares his vision of the UK as a life sciences reference market and his take…
Heading Accord Healthcare’s European, Middle East and North African operations, James Burt highlights the rapid growth the company has achieved within the region and how it has reached an impressive…
Promoting the UK’s capital in times of Brexit, Laura Citron, CEO at London & Partners, the international promotional agency of the Mayor of London, stresses the critical importance life sciences…
Erik Nordkamp, managing director of Pfizer UK, has been confirmed as the new president of the Association of the British Pharmaceutical Industry (ABPI). With UK life sciences still uncertain as…
Craig Wallace established the UK affiliate of Santen, the Japanese ophthalmology company, in 2014. Wallace describes the journey Santen has been on so far in the UK, as well as…
Britain, home of the discovery of the world’s first ever vaccine, has long been championing a pharma sub-segment forecast to reach a global market value of USD 49.27 billion by…
Thomas Bo Bjorn Klee, managing director of Lundbeck UK and Ireland, describes the global restructuring program Lundbeck initiated two years ago to ensure value creation, build on unique strengths and…
Having recently been able to present positive data for their lead technology IMCgp100 in uveal melanoma at the American Society of Clinical Oncology (ASCO), Immunocore looks at its future as…
Erik Nordkamp, managing director of Pfizer UK shares his thoughts on the future of healthcare and the role that Pfizer and the UK can play in shaping it. He explains…
Stewart Pearce, managing director of Otsuka UK and Ireland since 2017 discloses how he built up a leadership team fit for the Otsuka of 2023 and highlights what he appreciates…
As the UK extracts itself from the European Union, key figures from the country’s life sciences sector are split on the implications of Brexit for their industry. “The UK pharmaceutical…
See our Cookie Privacy Policy Here